Novartis

Adlai Nortye IPO gives old Novartis cancer drug new life
Adlai Nortye IPO gives old Novartis cancer drug new life
BioPharma Dive
Adlai Nortye
IPOs
Novartis
AN2025
head and neck cancer
solid tumors
Flag link:
Novartis confirms Sandoz spin-off for October 4, 2023
Novartis confirms Sandoz spin-off for October 4, 2023
Reuters
Novartis
Sandoz
spinoffs
Flag link:
Novartis eyes first-line use of Lutathera after trial win
Novartis eyes first-line use of Lutathera after trial win
Pharmaphorum
Novartis
radioligands
clinical trials
neuroendocrine tumors
Lutathera
Flag link:
FDA Regulatory Gauntlet Isn’t Getting Any Easier, Just Ask These Companies
FDA Regulatory Gauntlet Isn’t Getting Any Easier, Just Ask These Companies
BioSpace
FDA
ARS Pharmaceuticals
Novartis
Taysha
Alvotech
Intarcia
Flag link:
Novartis hit with another serious drug marketing breach, this time for multiple sclerosis therapy Mayzent
Novartis hit with another serious drug marketing breach, this time for multiple sclerosis therapy Mayzent
Fierce Pharma
Novartis
UK
PMCPA
pharma marketing
Mayzent
Flag link:
BeiGene to go solo with cancer drug after Novartis deal termination
BeiGene to go solo with cancer drug after Novartis deal termination
Yahoo/Reuters
BeiGene
Novartis
cancer
tislelizumab
Tivimbra
Flag link:
Bausch + Lomb seeks funding for eye drug acquisition from Novartis
Bausch + Lomb seeks funding for eye drug acquisition from Novartis
BioPharma Dive
Bausch + Lomb
Novartis
M&A
Xiidra
Flag link:
Novartis recalls Sandimmune oral solution due to crystal formation
Novartis recalls Sandimmune oral solution due to crystal formation
Pharmaceutical Technology
Novartis
product recalls
Sandimmune
organ transplants
Flag link:
Novartis Drops Eye Disease Gene Therapy from $800M Gyroscope Acquisition
Novartis Drops Eye Disease Gene Therapy from $800M Gyroscope Acquisition
BioSpace
Novartis
GT005
gene therapy
geographic atrophy
Gyroscope Therapeutics
Flag link:
Patent cliffs, divestitures and maturing biotechs all point to more pharma M&A: analysts
Patent cliffs, divestitures and maturing biotechs all point to more pharma M&A: analysts
Fierce Pharma
M&A
patent cliffs
Merck
JNJ
Pfizer
GSK
Novartis
Eli Lilly
Novo Nordisk
Flag link:
The 10 highest value R&D projects in biopharma
The 10 highest value R&D projects in biopharma
Fierce Biotech
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
Flag link:
Novartis names new board member after international boss steps down
Novartis names new board member after international boss steps down
Reuters
Novartis
executives
Patrick Horber
Marie-France Tschudin
Flag link:
Novartis files suit against IRA after blockbuster Entresto makes CMS' price negotiations list
Novartis files suit against IRA after blockbuster Entresto makes CMS' price negotiations list
Fierce Pharma
Novartis
legal
Inflation Reduction Act
CMS
drug pricing
Entresto
Flag link:
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
Motley Fool
Novartis
biosimilars
Eylea
Flag link:
Novartis updates on Sandoz finances ahead of spin-off
Novartis updates on Sandoz finances ahead of spin-off
Pharmaphorum
Novartis
Sandoz
spinoffs
generics
biosimilars
Flag link:
Novartis hits back at Entresto selection on Medicare list
Novartis hits back at Entresto selection on Medicare list
Pharmaphorum
Novartis
Entresto
drug pricing
Medicare
Flag link:
Novartis: Leqvio Provides Low-density Lipoprotein Cholesterol Reduction Beyond 6 Years Of Treatment
Novartis: Leqvio Provides Low-density Lipoprotein Cholesterol Reduction Beyond 6 Years Of Treatment
RTT News
Novartis
Leqvio
LDL cholesterol
clinical trials
Flag link:
Novartis Abandons Xoma-Partnered Antibody for Pancreatic Cancer
Novartis Abandons Xoma-Partnered Antibody for Pancreatic Cancer
BioSpace
Novartis
Xoma
NIS793
pancreatic cancer
Flag link:
FDA Decisions 2023: Sandoz, Gilead Sciences and More
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Flag link:
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
BioSpace
patent cliff
patents
Takeda
Vyvanse
Pfizer
Eraxis
JNJ
Stelara
Merck
Isentress
Eiger Pharmaceuticals
Zokinvy
Astellas
Myrbetriq
Novartis
Entresto
Amgen
Otzela
Flag link:

Pages